I am a seasoned and perseverent pre-clinical drug development neuroscientist with over 12 years of research experience covering NEUROSCIENCE, Biochemistry, Molecular and Cellular Biology, Synaptic Physiology and Stem Cell Biology. My "never give up" attitude and vast experience in many disciplines adopts me the ability to address scientific questions in creative and unique ways. I have experience in pre-clinical small molecule drug development to support chemistry SAR to identify lead therapeutic candidates for neurology related targets. Experience in design, optimization and execution of both cell based and biochemical assays. I can provide expertise in synaptic physiology, and neuropsychiatric disease modeling. I have comprehensively studied the biological basis of addiction utilizing human stem cell biology and cellular reprogramming techniques. I am well versed in cutting edge induced neuronal (iN) cell technology. My main roles at PTC as a preclinical drug development Neuroscientist: -Provide subject matter expertise and leadership in the expansion of neuroscience and neurological disease understanding -Design and execute high-throughput in-vitro cell-based assays to screen 100s of small molecules to assist in driving chemistry SAR -Validation of new drug targets accomplished through elegant experimental design (both cell-based and biochemical) -My main focus was elucidating the mechanism(s) of action of one of PTCs lead small molecule drug candidates for a rare neurological disorder -Comprehensively screened primary mouse neuronal cultures (as well as human cell lines) to identify disease specific biomarkers for pharmacodynamic studies -Mentored and trained associate level scientists on both the technical and conceptual framework of our teams small molecule pipeline -Translating in-vitro cell based findings into in-vivo rodent models to better understand the PK/PD relationship of our lead small molecule -Team lead for a gene-therapy focused project to combat a devastating rare pediatric indication ➢ Scientific communication is a great strength of mine. My experience has provided me with excellent presentation skills and the ability to convey my work to diverse audiences. https://www.ncbi.nlm.nih.gov/myncbi/matthew.scarnati.1/bibliography/public/ EMAIL: [email protected] SKILLS: Pre\-Clinical Drug Discovery I Electrophysiology \| Human Stem Cell Biology \| Mammalian Tissue Culture \| Cell Signaling Pathways \| Confocal Microscopy \| Protein Purification and Expression \| qPCR \| Cellular Assays \| Science Writing \| Problem Solving \| ELISA

Matthew Scarnati

Neuroscientist driving preclinical drug development programs to combat neurological disease.

Old Bridge, New Jersey, United States of America

Research Expertise

Neuroscience

Stem Cell Biology

Electrophysiology

Disease Modeling

Neuropsychiatric Disorders

About

Publications

Differential sensitivity of human neurons carrying μ opioid receptor (MOR) N40D variants in response to ethanol

Alcohol / Sep 01, 2020

Scarnati, M. S., Boreland, A. J., Joel, M., Hart, R. P., & Pang, Z. P. (2020). Differential sensitivity of human neurons carrying μ opioid receptor (MOR) N40D variants in response to ethanol. Alcohol, 87, 97–109. https://doi.org/10.1016/j.alcohol.2020.05.004

Addiction associated N40D mu-opioid receptor variant modulates synaptic function in human neurons

Molecular Psychiatry / Sep 03, 2019

Halikere, A., Popova, D., Scarnati, M. S., Hamod, A., Swerdel, M. R., Moore, J. C., Tischfield, J. A., Hart, R. P., & Pang, Z. P. (2019). Addiction associated N40D mu-opioid receptor variant modulates synaptic function in human neurons. Molecular Psychiatry, 25(7), 1406–1419. https://doi.org/10.1038/s41380-019-0507-0

Using human stem cells as a model system to understand the neural mechanisms of alcohol use disorders: Current status and outlook

Alcohol / Feb 01, 2019

Scarnati, M. S., Halikere, A., & Pang, Z. P. (2019). Using human stem cells as a model system to understand the neural mechanisms of alcohol use disorders: Current status and outlook. Alcohol, 74, 83–93. https://doi.org/10.1016/j.alcohol.2018.03.008

Active presynaptic ribosomes in the mammalian brain, and altered transmitter release after protein synthesis inhibition

eLife / Oct 30, 2018

Scarnati, M. S., Kataria, R., Biswas, M., & Paradiso, K. G. (2018). Active presynaptic ribosomes in the mammalian brain, and altered transmitter release after protein synthesis inhibition. ELife, 7. CLOCKSS. https://doi.org/10.7554/elife.36697

Active presynaptic ribosomes in mammalian brain nerve terminals, and increased transmitter release after protein synthesis inhibition

Apr 05, 2018

Scarnati, M. S., Kataria, R., Biswas, M., & Paradiso, K. G. (2018). Active presynaptic ribosomes in mammalian brain nerve terminals, and increased transmitter release after protein synthesis inhibition. https://doi.org/10.1101/295543

Neurotransmitter Release Can Be Stabilized by a Mechanism That Prevents Voltage Changes Near the End of Action Potentials from Affecting Calcium Currents

The Journal of Neuroscience / Nov 09, 2016

Clarke, S. G., Scarnati, M. S., & Paradiso, K. G. (2016). Neurotransmitter Release Can Be Stabilized by a Mechanism That Prevents Voltage Changes Near the End of Action Potentials from Affecting Calcium Currents. The Journal of Neuroscience, 36(45), 11559–11572. https://doi.org/10.1523/jneurosci.0066-16.2016

Oxidative-stress-induced nuclear to cytoplasmic relocalization is required for Not4-dependent cyclin C destruction

Journal of Cell Science / Feb 15, 2012

Cooper, K. F., Scarnati, M. S., Krasley, E., Mallory, M. J., Jin, C., Law, M. J., & Strich, R. (2012). Oxidative-stress-induced nuclear to cytoplasmic relocalization is required for Not4-dependent cyclin C destruction. Journal of Cell Science, 125(4), 1015–1026. https://doi.org/10.1242/jcs.096479

Education

Rutgers University - Busch Campus

PhD, Cell Biology and Neuroscience / December, 2017

Piscataway, New Jersey, United States of America

UMDNJ-School of Osteopathic Medicine Department of Molecular Biology

PhD Student , Molecular Biology / May, 2013

Stratford, New Jersey, United States of America

Stockton University

BS Biochemistry and Molecular Biology, Biochemsitry and Molecular Biology / May, 2009

Galloway, New Jersey, United States of America

Experience

Rutgers Robert Wood Johnson Medical School New Brunswick

Postdoctoral Fellow / January, 2018 — January, 2021

PTC Therapeutics, Inc.

Scientist II / January, 2022 — January, 2024

Eternity Biosciences INC

Senior Research Investigator / May, 2021 — November, 2021

NJ Department of Health

Research Scientist III / February, 2021 — May, 2021

Join Matthew on NotedSource!

Join Now

At NotedSource, we believe that professors, post-docs, scientists and other researchers have deep, untapped knowledge and expertise that can be leveraged to drive innovation within companies. NotedSource is committed to bridging the gap between academia and industry by providing a platform for collaboration with industry and networking with other researchers.

For industry, NotedSource identifies the right academic experts in 24 hours to help organizations build and grow. With a platform of thousands of knowledgeable PhDs, scientists, and industry experts, NotedSource makes connecting and collaborating easy.

For academic researchers such as professors, post-docs, and Ph.D.s, NotedSource provides tools to discover and connect to your colleagues with messaging and news feeds, in addition to the opportunity to be paid for your collaboration with vetted partners.

Expert Institutions

Proudly trusted by

Connect with researchers and scientists like Matthew Scarnati on NotedSource to help your company with innovation, research, R&D, L&D, and more.

Events

Blog

Case Studies

Resources